Thiel Bio | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Thiel Bio/Activity

Thiel Bio Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

4 investments· SEP 2024 – OCT 2025Show all

Investment

Co-invested in HistoSonics' oversubscribed $250M growth financing at a $3B+ valuation for its sound-wave tumor ablation therapy.

HistoSonics

HistoSonics Thiel Bio

businesswire.comOCT 16, 2025

OCT 16, 2025

Investment

Co-led (with Presight Capital and Founders Fund) Peptilogics' oversubscribed $78M Series B2 to advance zaloganan into a pivotal trial.

Peptilogics

Peptilogics Thiel Bio

prnewswire.comOCT 2025

OCT 2025

Investment

Participated in Ataraxis AI's $20.4M Series A for its AI-native breast cancer diagnostics platform, alongside Founders Fund and AIX Ventures.

Ataraxis

Ataraxis Thiel Bio

businesswire.comMAR 4, 2025

MAR 4, 2025

Investment

Continued backing of EnClear Therapies' neuro-oncology CSF management platform alongside Founders Fund and Amgen Ventures.

EnClear Therapies

EnClear Therapies Thiel Bio

biospace.comSEP 3, 2024

SEP 3, 2024

New Fund

Jason Camm registered Thiel Bio, a ~$100M single-LP fund focused on biotechnology and life sciences investing.

Thiel Bio Fund

news.bloomberglaw.comJUL 2023

JUL 2023